TY - JOUR
T1 - Evaluation of Survival and Postoperative Radiation Among Patients with Advanced Medullary Thyroid Carcinoma
T2 - An Analysis of the National Cancer Database
AU - Ow, Thomas J.
AU - Mehta, Vikas
AU - Kim, Seokhwa
AU - Vakil, Mayand
AU - Friedmann, Patricia
AU - In, Haejin
N1 - Funding Information:
The efforts of Drs. T. J. Ow and H. In were supported by NIH-NCI Grant 2K12 CA132783-06. The contribution of Dr. T. J. Ow also was supported by NIH/National Center for Advancing Translational Science (NCATS) Einstein-Montefiore CTSA (Grant No. UL1TR001073) and by NIH-NIDCR K23 (Grant No. 1 K23 DE027425-01). The manuscript content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
Dr. T. J. Ow is the site Principal Investigator for a phase 0 study supported by Presage Biosceinces, Inc., with sub-studies sponsored by Takeda (Millenium Pharmaceuticals, Inc.) and Bristol Myers Squibb. The phase 0 study is not focused on medullary thyroid carcinoma or radiation treatment. The remaining authors have no conflicts of interest.
Publisher Copyright:
© 2022, Society of Surgical Oncology.
PY - 2022/4
Y1 - 2022/4
N2 - Background: This study compared survival between patients who had medullary thyroid cancer (MTC) treated with surgery alone and patients who underwent surgery and radiation (SRT). Methods: Patients from the National Cancer Database (NCDB) with a diagnosis of stage 3 or 4 MTC, lymph node disease, and no distant metastases between 2008 and 2016 were studied. Kaplan–Meier analyses and log-rank statistics were used to estimate and compare overall survival between patients treated with surgery alone and those treated with SRT. Mutlivariable Cox proportional hazards models and propensity-matching were used to adjust for confounding and selection bias. Results: Among 1370 patients, 1112 (81%) received surgery alone, and 258 (19%) received SRT. The hazard ratio for mortality in the SRT group was 1.784 (95% confidence interval [CI] 1.313–2.43) after multivariable adjustment for confounding variables. Furthermore, SRT remained associated with a higher mortality rate (p < 0.008) after propensity-matching in an effort to adjust for selection bias. Conclusions: This analysis of NCDB patients showed that SRT is associated with a significantly higher mortality rate among patients treated for stage 3 or 4 IV MTC with positive lymph node disease. Although this observation can be attributed to unmeasured confounders or selection bias, the cause for the profound survival differences deserves prospective evaluation, especially as adjuvant therapies for this disease continue to evolve.
AB - Background: This study compared survival between patients who had medullary thyroid cancer (MTC) treated with surgery alone and patients who underwent surgery and radiation (SRT). Methods: Patients from the National Cancer Database (NCDB) with a diagnosis of stage 3 or 4 MTC, lymph node disease, and no distant metastases between 2008 and 2016 were studied. Kaplan–Meier analyses and log-rank statistics were used to estimate and compare overall survival between patients treated with surgery alone and those treated with SRT. Mutlivariable Cox proportional hazards models and propensity-matching were used to adjust for confounding and selection bias. Results: Among 1370 patients, 1112 (81%) received surgery alone, and 258 (19%) received SRT. The hazard ratio for mortality in the SRT group was 1.784 (95% confidence interval [CI] 1.313–2.43) after multivariable adjustment for confounding variables. Furthermore, SRT remained associated with a higher mortality rate (p < 0.008) after propensity-matching in an effort to adjust for selection bias. Conclusions: This analysis of NCDB patients showed that SRT is associated with a significantly higher mortality rate among patients treated for stage 3 or 4 IV MTC with positive lymph node disease. Although this observation can be attributed to unmeasured confounders or selection bias, the cause for the profound survival differences deserves prospective evaluation, especially as adjuvant therapies for this disease continue to evolve.
UR - http://www.scopus.com/inward/record.url?scp=85123472636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123472636&partnerID=8YFLogxK
U2 - 10.1245/s10434-021-11158-9
DO - 10.1245/s10434-021-11158-9
M3 - Article
C2 - 35001236
AN - SCOPUS:85123472636
SN - 1068-9265
VL - 29
SP - 2582
EP - 2591
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -